Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases - PubMed (original) (raw)

Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases

Derek L Dai et al. J Clin Oncol. 2005.

Abstract

Purpose: Akt is a serine/threonine kinase that leads to stimulation of cell cycle progression, cell proliferation, and inhibition of apoptosis. To investigate the role of Akt in melanoma pathogenesis, we examined the expression of phospho-Akt (p-Akt; Ser-473) in melanocytic lesions at different stages and analyzed the correlations between the p-Akt expression level and clinicopathologic factors and patient survival.

Patients and methods: We evaluated the p-Akt expression in 12 cases of normal nevi, 58 cases of dysplastic nevi, 170 cases of primary melanomas, and 52 cases of melanoma metastases using tissue microarray and immunohistochemistry.

Results: Strong p-Akt expression was observed in 17%, 43%, 49%, and 77% of the biopsies in normal nevi, dysplastic nevi, primary melanoma, and melanoma metastases, respectively. Significant differences for p-Akt staining pattern were observed between normal nevi and primary melanomas (P < .05), and between primary melanomas and melanoma metastases (P < .001). Furthermore, our Kaplan-Meier survival curves showed that strong p-Akt expression is inversely correlated with both overall and disease-specific 5-year survival of patients with primary melanoma (P < .05 for both). Strikingly, our multivariate Cox regression analysis revealed that p-Akt is an independent prognostic factor in low-risk melanomas (thickness < or = 1.5 mm; relative risk, 6.44; 95% CI, 1.28 to 32.55; P = .018).

Conclusion: The expression of p-Akt increases dramatically with melanoma invasion and progression and is inversely correlated with patient survival. In addition, p-Akt may serve as an independent prognostic marker and help to identify those patients with low-risk melanomas who are at increased risk of death.

PubMed Disclaimer

Cited by

MYH6 suppresses tumor progression by downregulating KIT expression in human prostate cancer.
Wang F, Shen H, Li K, Ding Y, Wang J, Sun J. Wang F, et al. Sci Rep. 2024 Aug 24;14(1):19685. doi: 10.1038/s41598-024-70665-3. Sci Rep. 2024. PMID: 39181964 Free PMC article.
Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.
Vredeveld LC, Possik PA, Smit MA, Meissl K, Michaloglou C, Horlings HM, Ajouaou A, Kortman PC, Dankort D, McMahon M, Mooi WJ, Peeper DS. Vredeveld LC, et al. Genes Dev. 2012 May 15;26(10):1055-69. doi: 10.1101/gad.187252.112. Epub 2012 May 1. Genes Dev. 2012. PMID: 22549727 Free PMC article.
[Molecular heterogeneity of malignant melanomas].
Glatz K. Glatz K. Pathologe. 2007 Nov;28(6):474-8. doi: 10.1007/s00292-007-0942-6. Pathologe. 2007. PMID: 17885757 German.
Expression of activated Akt in benign nevi, Spitz nevi and melanomas.
Kantrow SM, Boyd AS, Ellis DL, Nanney LB, Richmond A, Shyr Y, Robbins JB. Kantrow SM, et al. J Cutan Pathol. 2007 Aug;34(8):593-6. doi: 10.1111/j.1600-0560.2006.00675.x. J Cutan Pathol. 2007. PMID: 17640227 Free PMC article.
Genetics and genomics of melanoma.
Ghosh P, Chin L. Ghosh P, et al. Expert Rev Dermatol. 2009 Apr 1;4(2):131. doi: 10.1586/edm.09.2. Expert Rev Dermatol. 2009. PMID: 20126509 Free PMC article.

Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases - PubMed (original) (raw)